PAHO regional meeting of health ministers concludes with new measures to strengthen health security and address key health threats - Pan American Health Organization (PAHO)
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Health authorities approved new regional strategies to strengthen preparedness for health emergencies, tackle antimicrobial resistance, curb dengue and other arboviral diseases, and improve food safety, while advancing access to vaccines, medicines and other essential health technologies across the Americas. Washington, D. C., 2 October 2026 (PAHO) – The 63rd Directing Council of the Pan American Health Organization (PAHO) concluded with countries of the Americas approving a series of decisions aimed at strengthening preparedness for increasingly frequent health emergencies, addressing antimicrobial resistance, reducing the growing burden of dengue and other arboviral diseases, improving food safety, and expanding access to health technologies. Over five days, Ministers of Health and other senior health authorities from across the Americas met in Washington, D. C., to discuss key public health priorities, review progress on regional initiatives and adopt decisions aimed at strengthening health systems and advancing health and well-being across the Region. “The resolutions and decisions adopted during this Council will guide our work in the years ahead.
This article is an excerpt. To read the full content, visit the original source. Pan American Health Organization (PAHO)
Related articles
Pandemic Digital Memorial concludes its first phase - Pan American Health Organization (PAHO)
Bioengineer.org | Switching HIV drugs or adding zoledronic acid rebuilds bone lost to tenofovir - European AIDS Treatment Group
Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.
A New Injection Makes Fat Cells Self-Destruct, And Might Prevent GLP-1 Weight Regain - ScienceAlert
The new treatment kills off a sub-group of fat cells. (Jian Fan/iStockphoto/Getty Images) Early clinical trials into a new fat reduction treatment have reported promising results, and the treatment takes a more unusual approach: Rather than shrinking fat cells, as most weight loss strategies do, it safely and naturally kills them off. The drug here is CBL-514, which is administered via injection. As well as proving effective at reducing subcutaneous fat (just below the skin), there's evidence it can also reduce visceral fat (stored deeper around the organs). According to the team behind the trials, CBL-514 and its unconventional strategy have the potential to reduce fat in key areas of the body – with further benefits that come with weight loss likely to follow. "We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss," says endocrinologist Timothy Garvey, from the University of Alabama at Birmingham, who headed up the trial.
0 comments
No comments yet. Be the first to share your thoughts!